Profusa
Injectable hydrogel biosensors and optical readers for continuous body-chemistry monitoring.
Something off on this page? Send us feedback.
Profile
Develops Lumee injectable hydrogel biosensors, optical readers, and software for tissue oxygen and clinical-stage glucose monitoring. The company is pre-revenue and relies on regulatory authorization, particularly European MDR certification for Lumee Oxygen, before clinical commercialization.
Develops Lumee, which pairs injectable, tissue-integrated hydrogel biosensors with wearable optical readers and mobile software to continuously measure body chemistry. Lumee Oxygen monitors local tissue oxygen, and Lumee Glucose is a clinical-stage continuous-glucose-monitoring candidate. Research-use tissue-oxygen kits and service-enabled offerings are available to contract research organizations, while clinical commercialization has not begun.
Separates a passive injectable sensor from a reusable optical reader; the hydrogel contains no electronics or power source, while reader software turns fluorescence and temperature data into values. Research, management, and most implantable-sensor production are in Berkeley, supported by qualified outside vendors. Europe is Lumee Oxygen's lead clinical-commercial geography, but its commercialization depends on MDR certification; neither Lumee Oxygen nor Lumee Glucose holds U.S. marketing authorization.
Company facts
Categories
Key statistics
Year to date −99.6% · Average volume (30d) 2.2M
Analysts
No analyst consensus on record.
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 19, 2026Q2 FY26 | — | −$151.80 | — | — | — | — | −50.62% |
| May 15, 2026Q1 FY26 | — | −$2.05 | — | — | — | — | −1.98% |
| Apr 1, 2026Q4 FY25 | — | −$6.95 | — | — | — | — | +30.96% |
| Nov 19, 2025Q3 FY25 | — | −$52.63 | — | — | — | — | −19.64% |
Financial highlights
| 11 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | |
| Gross profit | $0 | $0 | $0 | $0 | $0 | −$2.0K | |
| Operating income | −$1.4M | −$967.1K | −$21.7M | −$3.6M | −$4.0M | −$2.5M | |
| Net income | −$2.7M | −$8.2M | −$22.2M | −$8.6M | −$3.5M | −$8.8M | |
| Diluted EPS | −$7,881.91 | −$118.37 | −$52.45 | −$6.95 | −$2.05 | −$151.80 | |
| Gross margin | — | — | — | — | — | — | |
| Operating margin | — | — | — | — | — | — |
Fiscal years (4-quarter sums)FY24 $0 · FY25 $0
Balance sheet, Jun 30, 2026Cash & short-term investments $719.0K · Total debt $14.0M · Total assets $1.0M · Shareholders' equity −$27.1M
Dividends
No dividends on record.
Ownership
Shares outstanding 1.10M · Float —
Float — provider float is below the insider stake.
A split settled inside the quarter being compared, so quarter-on-quarter change is not shown.
The provider's float is smaller than the insider stake it should exclude, so it is not shown.
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Fred S. Knechtel · officer: Chief Financial Officer | 302.1K | 27.40% | Form 4 | Aug 19, 2026 |
| Jack E. Stover · officer: Chief Executive Officer | 302.1K | 27.40% | Form 4 | Aug 19, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 17, 2026 | HRT Financial LP | 10 percent owner | −18,395 | $5.94 |
| Aug 14, 2026 | HRT Financial LP | 10 percent owner | −3,163 | $0.9020 |
| Aug 13, 2026 | HRT Financial LP | 10 percent owner | −42,411 | $0.8880 |
| Aug 12, 2026 | HRT Financial LP | 10 percent owner | +5,585 | $0.9640 |
| Aug 11, 2026 | HRT Financial LP | 10 percent owner | −2,280 | $0.9700 |
Peers
- Dexcom
Scaled CGM incumbent across personal and professional use.
- Abbott
FreeStyle Libre is a major commercial CGM alternative.
- Senseonics
Long-duration implantable CGM alternative with a one-year sensor.
- Medtronic
Simplera and MiniMed combine CGM with insulin delivery.
- Philips (ADR)
Angiography and CT compete for peripheral-perfusion workflow.
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Profusa | $2.79 | −3.46% | $3.2M | — | — | — | — |
| Dexcom | $90.77 | −0.06% | $34.27B | 35.9 | 32.4 | 6.9 | +13.1% |
| Abbott | $112.20 | −0.22% | $194.62B | 36.2 | 19.4 | 4.2 | +13.0% |
| Senseonics | $9.37 | +0.54% | $389.9M | — | — | 8.0 | +118.1% |
| Medtronic | $91.58 | +0.42% | $116.78B | 24.5 | 15.3 | 3.2 | +9.9% |
| Philips (ADR) | $26.72 | +0.06% | $26.12B | 19.9 | 13.7 | 1.3 | −2.9% |
| Median | 30.2 | 17.3 | 4.2 | +13.0% |